Thomas Lynch | Academic Influence

Thomas Lynch 's AcademicInfluence.com Rankings

Thomas Lynch

Computer Science

#7999

World Rank

#8417

Historical Rank

Machine Learning

#3152

World Rank

#3191

Historical Rank

Artificial Intelligence

#3453

World Rank

#3503

Historical Rank

Database

#5049

World Rank

#5246

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Thomas Lynch 's Degrees

PhD Computer Science Stanford University

Similar Degrees You Can Earn

Best Online PhD of Computer Science (Doctorates) 2026

Why Is Thomas Lynch Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Thomas Lynch is a professor at the University of Washington School of Drama. He teaches graduate students exclusively in opera scenery design. Education Lynch completed his MFA at Yale under the supervision of Chinese American theatrical set designer Ming Cho Lee.

(See a Problem?)

Thomas Lynch 's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. (2004) (10991)
Early palliative care for patients with metastatic non-small-cell lung cancer. (2010) (4607)
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. (2010) (3445)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors (2011) (3017)
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. (2003) (2609)
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. (2009) (1717)
Detection of mutations in EGFR in circulating lung-cancer cells. (2008) (1334)
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. (2005) (940)
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. (2008) (845)
Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population (2009) (646)
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. (2005) (618)
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. (2012) (599)
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. (2013) (563)
Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib (2006) (549)
Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. (2011) (548)
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. (2007) (516)
Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. (2010) (447)
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. (2010) (402)
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine (2010) (391)
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. (2011) (353)
Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. (2007) (345)
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. (2004) (313)
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. (2007) (309)
Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy (2004) (294)
A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors (2009) (276)
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. (2010) (267)
EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. (2010) (244)
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. (1993) (224)
A phase II study of gefitinib in patients with advanced thyroid cancer. (2007) (210)
FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. (2002) (209)
Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. (2007) (200)
Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. (2003) (200)
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. (2004) (195)
A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. (2001) (192)
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. (2006) (182)
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. (2007) (176)
The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. (2009) (175)
Gene-environment interaction for the ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer. (2002) (165)
A Structured Exercise Program for Patients with Advanced Non-small Cell Lung Cancer (2009) (161)
EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. (2008) (146)
Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. (1995) (145)
Behavioral and psychological predictors of chemotherapy adherence in patients with advanced non-small cell lung cancer. (2008) (139)
Vitamin D Is Associated with Improved Survival in Early-Stage Non–Small Cell Lung Cancer Patients (2005) (134)
Manganese superoxide dismutase alanine-to-valine polymorphism at codon 16 and lung cancer risk. (2001) (133)
Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. (2002) (131)
A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non–Small-Cell Lung Cancer (2012) (131)
Phase II study: integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients. (2007) (127)
Polymorphisms in ERCC1 and Grade 3 or 4 Toxicity in Non–Small Cell Lung Cancer Patients (2005) (127)
Burnout: caring for the caregivers. (2000) (124)
Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. (2001) (124)
Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. (2008) (124)
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. (2005) (121)
Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. (2002) (121)
Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. (2008) (120)
VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. (2008) (119)
Breaking bad news: a patient's perspective. (2003) (113)
Cancer as metaphor. (2004) (112)
Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib (2008) (110)
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer (2015) (110)
Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. (2005) (107)
The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. (2003) (107)
A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. (2001) (106)
Phase II study of topotecan in metastatic non-small-cell lung cancer. (1994) (106)
Gene-Smoking Interaction Associations for the ERCC1 Polymorphisms in the Risk of Lung Cancer (2005) (105)
Aggressiveness of care in a prospective cohort of patients with advanced NSCLC (2008) (103)
Sedation for intractable distress of a dying patient: acute palliative care and the principle of double effect. (2000) (99)
Induction chemoradiation compared with induction radiation for lung cancer involving the superior sulcus. (2002) (97)
Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. (2001) (97)
Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. (2009) (97)
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. (2001) (93)
B3-03: A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC) (2007) (92)
Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. (2006) (92)
The interaction between microsomal epoxide hydrolase polymorphisms and cumulative cigarette smoking in different histological subtypes of lung cancer. (2001) (92)
Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). (1997) (90)
Second hand smoke, age of exposure and lung cancer risk. (2007) (88)
Integration of Molecular Profiling into the Lung Cancer Clinic (2009) (85)
Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients (2006) (84)
A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer (2015) (82)
Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer. (2002) (77)
The NAD(P)H:quinone oxidoreductase 1 gene polymorphism and lung cancer: differential susceptibility based on smoking behavior. (2001) (77)
Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. (1997) (76)
Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer (2010) (75)
SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. (2014) (75)
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function (2016) (75)
Depression after diagnosis of advanced non-small cell lung cancer and survival: a pilot study. (2008) (75)
A Phase II trial of gemcitabine for metastatic neuroendocrine tumors (2004) (73)
Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes (2009) (73)
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up (2017) (73)
Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients. (2006) (73)
Radiation dose escalation in limited-stage small-cell lung cancer. (2003) (71)
Laughter: the best medicine? (2005) (70)
Comprehensive symptom management in patients with advanced-stage non-small-cell lung cancer. (2006) (69)
Vascular Endothelial Growth Factor Genotypes, Haplotypes, Gender, and the Risk of Non–Small Cell Lung Cancer (2008) (68)
Sexuality and cancer: conversation comfort zone. (2000) (67)
Management of malignant pleural effusions. (1993) (67)
Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. (1997) (65)
Dietary Iron, Zinc, and Calcium and the Risk of Lung Cancer (2005) (65)
Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. (2014) (64)
Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. (2008) (63)
Counterpoint: the myeloperoxidase -463G-->a polymorphism does not decrease lung cancer susceptibility in Caucasians. (2002) (62)
Polymorphisms of Vitamin D Receptor and Survival in Early-Stage Non–Small Cell Lung Cancer Patients (2006) (62)
Matrix Metalloproteinase-1 Promoter Polymorphism and Lung Cancer Risk (2005) (61)
A decade of advances in treatment for advanced non-small cell lung cancer. (2011) (61)
HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors. (2006) (61)
MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. (2007) (59)
XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk. (2007) (57)
A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer (2009) (57)
MPO and SOD2 polymorphisms, gender, and the risk of non-small cell lung carcinoma. (2004) (56)
Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC). (2010) (54)
O-108 Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC (2003) (53)
Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. (2008) (53)
A phase II study of the immunotoxin N901-blocked ricin in small-cell lung cancer. (2002) (52)
Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment (2008) (52)
Vascular Endothelial Growth Factor Polymorphisms and Esophageal Cancer Prognosis (2009) (52)
Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study (2014) (52)
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors (2006) (51)
A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC). (2004) (51)
Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents (2006) (49)
Direct-to-consumer advertising in oncology. (2006) (49)
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. (2017) (49)
The SOD2 Val/Val genotype enhances the risk of nonsmall cell lung carcinoma by p53 and XRCC1 polymorphisms (2004) (49)
Smoking and the Risk of Lung Cancer: Susceptibility with GSTP1 Polymorphisms (2003) (47)
Medical mistakes: a workshop on personal perspectives. (2001) (44)
p53 Arg72Pro and MDM2 T309G Polymorphisms, Histology, and Esophageal Cancer Prognosis (2009) (43)
Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma. (1993) (43)
Lost in translation: integrating medical interpreters into the multidisciplinary team. (2008) (42)
Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): Results from ARIES, a bevacizumab (BV) observational cohort study (OCS). (2010) (42)
Fear of death. (2005) (41)
Role of chemotherapy in the management of advanced thymic tumors. (2005) (41)
The impact of a physician awareness group and the first year of training on hematology-oncology fellows. (2003) (41)
Feasibility and Validity of a One-Item Fatigue Screen in a Thoracic Oncology Clinic (2006) (41)
p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma. (2010) (41)
When does the responsibility of our care end: bereavement. (2002) (41)
Multimodality therapy of patients with stage IIIA, N2 non-small-cell lung cancer. Impact of preoperative chemotherapy on resectability and downstaging. (1993) (40)
Teams: communication in multidisciplinary care. (2006) (40)
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. (1996) (39)
Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer (2012) (39)
Matrix Metalloproteinase Polymorphisms and Survival in Stage I Non–Small Cell Lung Cancer (2006) (39)
Immunotoxin therapy of small-cell lung cancer. N901-blocked ricin for relapsed small-cell lung cancer. (1993) (38)
Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial (2008) (38)
P53 (codon 72) and P21 (codon 31) polymorphisms alter in vivo mRNA expression of p21. (2003) (37)
Race, ethnicity, and the patient-caregiver relationship. (2002) (36)
The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). (2012) (36)
Too old to care? (2004) (35)
A Phase II Study of Oxaliplatin, Pemetrexed, and Bevacizumab in Previously Treated Advanced Non-small Cell Lung Cancer (2008) (35)
Complementary, alternative, integrative, or unconventional medicine? (2001) (34)
Phase I Trial of the Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin and Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer (2005) (34)
A phase II study of KOS-862 (epothilone D) as second-line therapy in non-small cell lung cancer (2005) (33)
Virtual connections: Internet health care. (2002) (33)
Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors (2004) (33)
Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. (2006) (32)
Quality indicators in cancer care: development and implementation for improved health outcomes in non-small-cell lung cancer. (2009) (31)
A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion (2000) (30)
An association between glutathione S‐transferase P1 gene polymorphism and younger age at onset of lung carcinoma (2006) (30)
Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized phase II/III trials (2009) (29)
Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. (1998) (28)
Harrison's Manual of Oncology (2007) (28)
No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk. (2003) (27)
Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS). (2009) (27)
Optimal therapy of malignant pleural effusions. (1996) (27)
Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430). (2002) (27)
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors (2000) (26)
A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. (2002) (26)
Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study. (2004) (25)
Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer: Predicting Clinical Response to Kinase Inhibitors (2005) (25)
iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors (2007) (24)
Toward noninvasive genomic screening of lung cancer patients. (2009) (24)
Clinical trials with blocked ricin immunotoxins. (1998) (23)
Correlation of molecular markers including mutations with clinical outcomes in advanced non small cell lung cancer (NSCLC) patients (pts) treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trials (2005) (23)
Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients > 70 years of age with previously untreated advanced non-small cell lung carcinoma (2004) (23)
Reality testing in cancer treatment: the phase I trial of endostatin. (2002) (23)
Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS) (2008) (22)
Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer (2009) (22)
Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once a Week for 3 of 4 Weeks in Patients with Advanced Solid Tumors (2009) (22)
Second Hand Smoke Exposure and Survival in Early-Stage Non–Small-Cell Lung Cancer Patients (2006) (21)
Between parent and child: negotiating cancer treatment in adolescents. (2002) (21)
Learning to cope: how far is too close? (2005) (20)
Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer. (2009) (19)
Novel agents in the treatment of lung cancer: conference summary statement. (2004) (18)
Help me help you: support groups in cancer therapy. (2004) (18)
Effect of recombinant human interleukin‐3 on haematological recovery from chemotherapy‐induced myelosuppression (1994) (18)
Clinical outcomes in elderly patients with advanced non-small cell lung cancer: results from ARIES, a bevacizumab observational cohort study. (2015) (18)
Phase I Study of the c-raf-1 Antisense Oligonucleotide ISIS 5132 in Combination with Carboplatin and Paclitaxel in Patients with Previously Untreated, Advanced Non-small Cell Lung Cancer (2009) (18)
Phase II study of the EGFR tyrosine kinase erlotinib in patients ≥ 70 years of age with previously untreated advanced non-small cell lung carcinoma (2005) (18)
Polymorphisms of inflammatory and metalloproteinase genes, Helicobacter pylori infection and the risk of oesophageal adenocarcinoma (2008) (17)
Connection: Schwartz Center Rounds at Massachusetts General Hospital Cancer Center. (2010) (17)
Cisplatin, 5‐fluorouracil, and etoposide for advanced non‐small cell lung cancer (1993) (16)
203 POSTER Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer (2008) (16)
Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy. (2009) (16)
Living as a cancer surpriser: a doctor tells his story. (2003) (16)
Phase I/II trial of the novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or refractory stage IIIB or stage IV non-small cell lung cancer stratified by EGFR mutation status (2007) (16)
Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy (2008) (16)
Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes! (2003) (15)
A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC). (2013) (15)
Trials of 9‐Amino‐20(S)‐Camptothecin in Boston (1996) (15)
A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status. (2009) (15)
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. (2016) (15)
Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma. (2009) (14)
Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non--small cell lung cancer. (2001) (14)
Choosing optimal antimicrobial therapies. (2012) (13)
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. (2018) (13)
Phase II trial of oxaliplatin, pemetrexed, and bevacizumab in previously-treated advanced non-small cell lung cancer (NSCLC) (2007) (13)
Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer. (2012) (13)
A staff dialogue on do not resuscitate orders: psychosocial issues faced by patients, their families, and caregivers. (1999) (13)
K-Ras mutation (mut), EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: Retrospective analyses of the BMS099 trial. (2009) (13)
O-243 Clinical benefits in patients with advanced non-small-cell lung cancer treated with gefitinib (“Iressa”, ZD1839) in the compassionate use program (2003) (12)
A Rapid Outcomes Ascertainment System Improves the Quality of Prognostic and Pharmacogenetic Outcomes from Observational Studies (2008) (12)
Lung cancer highlights. (2000) (12)
The evolving story of the epidermal growth factor receptor as a target for non-small-cell lung cancer. (2004) (12)
Effect of early palliative care (PC) on quality of life (QOL), aggressive care at the end-of-life (EOL), and survival in stage IV NSCLC patients: Results of a phase III randomized trial. (2010) (12)
Novel Agents in the Treatment of Lung Cancer (2004) (12)
Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients > 70 years of age with previously untreated advanced non-small cell lung carcinoma. (2004) (12)
Faith, identity, and leukemia: when blood products are not an option. (2002) (12)
A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer. (1995) (12)
Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies (2001) (12)
Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference (2007) (11)
Phase II trial of erlotinib in elderly patients (age > 70) with previously untreated advanced non-small cell lung cancer (NSCLC): An analysis of quality of life and symptom response. (2006) (11)
A Phase II Study of Doxorubicin, Cisplatin, and 5-Fluorouracil in Patients with Advanced Adenocarcinoma of the Stomach or Esophagus (2006) (11)
Baseline (BL) radiographic characteristics and severe pulmonary hemorrhage (SPH) in bevacizumab (BV)-treated non-small cell lung cancer (NSCLC) patients (pt): Results from ARIES, an observational cohort study (OCS). (2010) (10)
Potential of 18F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer (2013) (10)
Erratum: Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up [Ann Oncol, 28, 1, (2017) (75-82)] DOI: 10.1093/annonc/mdw436 (2017) (10)
Randomized phase II study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer (NSCLC) (2007) (10)
Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors. (2003) (9)
Losing God. (2001) (9)
A staff dialogue on aggressive palliative treatment demanded by a terminally ill patient: psychosocial issues faced by patients, their families, and caregivers. (2002) (9)
The Kenneth B. Schwartz Center at Massachusetts General Hospital hematology-oncology department: hope for the homeless. (2003) (9)
The role of adjuvant chemotherapy for non-small cell lung cancer. (2005) (9)
9001 ORAL A Retrospective Subgroup Analysis of EGFR Immunohistochemistry (IHC) Expression by Histo-Score Correlated to Outcomes From the BMS099 1st Line Phase III NSCLC Trial of Cetuximab (Cet) Plus Carboplatin/Taxane (2011) (9)
Clinicopathologic features of EML4-ALK mutant lung cancer. (2009) (8)
Unmet challenges in the use of novel agents in locally advanced non-small-cell lung cancer. (2012) (8)
Phase I/II study of AT-101 in combination with topotecan in patients with relapsed or refractory small cell lung cancer after prior platinum containing first line chemotherapy (2008) (8)
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 26-2004. A 56-year-old woman with cough and a lung nodule. (2004) (8)
Early Stage Lung Cancer—New Approaches to Evaluation and Treatment: Conference Summary Statement (2005) (7)
Continuous‐infusion cisplatin, 5‐fluorouracil, and leucovorin for advanced non‐small cell lung cancer (1994) (7)
A phase I study of carboplatin (Car) and docetaxel (Doc) followed by weekly Car/Doc with concurrent radiotherapy (CT/RT) in patients (pts) with stage III non-small cell lung cancer (NSCLC) (2000) (7)
Phase II Trial of Vinorelbine Plus Doxorubicin in Relapsed Small-Cell Lung Cancer: CALGB 9332 (2004) (7)
Epidermal Growth Factor Receptor Inhibitors (2008) (7)
Medical oncologists’ clinical experiences and comfort levels with 20 recently approved agents. (2013) (6)
Choosing chemotherapy for lung cancer based on cost: not yet. (2002) (6)
Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study (2015) (6)
Phase I dose‐escalation study of tezacitabine in combination with 5‐fluorouracil in patients with advanced solid tumors (2005) (6)
A randomized, open-label, phase III trial of NOV-002 in combination with paclitaxel (P) and carboplatin (C) versus paclitaxel and carboplatin alone for the treatment of advanced non-small cell lung cancer (NSCLC). (2010) (6)
9009 A meta-analysis of four randomized phase II/III trials adding cetuximab to platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC) (2009) (6)
The NAD(P)H:quinone Oxidoreductase 1 Gene Polymorphism and Lung Cancer (2001) (5)
CT screening for lung cancer. (2007) (5)
Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis. (1997) (5)
p 53 Arg 72 Pro and MDM 2 T 309 G Polymorphisms , Histology , and Esophageal Cancer Prognosis (2009) (5)
Neo-adjuvant radiation, cisplatin, 5-FU +/− paclitaxel in locally advanced esophageal cancer (2004) (5)
Prognostic significance of nuclear excision (NER) and base excision (BER) DNA repair gene polymorphisms in esophageal cancer (2007) (5)
Epidermal growth factor receptor tyrosine kinase inhibitors and depression. (2009) (5)
Illness understanding in patients with advanced lung cancer. (2009) (5)
A phase II clinical and pharmacokinetic study of weekly paclitaxel in elderly patients with non-small cell lung cancer (2000) (4)
Gene-Environment Interaction for the ERCC 2 Polymorphisms and Cumulative Cigarette Smoking Exposure in Lung Cancer 1 (2002) (4)
Counterpoint: The Myeloperoxidase (cid:1) 463 G 3 A Polymorphism Does Not Decrease Lung Cancer Susceptibility in Caucasians 1 (2002) (4)
Caring for colleagues. (2001) (4)
Duct tape removes warts. (2003) (4)
114 Preoperative accelerated radiotherapy (RT) and concurrent chemotherapy (CT) for stage IIIA (N2) non-small cell lung cancer (NSCLC): Improved survival by enhanced local tumor control (1995) (4)
Predictive tests for EGFR inhibitors. (2005) (4)
Polymorphisms in the DNA Repair Genes XRCC 1 and ERCC 2 , Smoking , and Lung Cancer Risk 1 (2003) (4)
Trust violated: analgesics for addicts. (2003) (4)
The effect of depression on survival in patients with newly diagnosed advanced non-small cell lung cancer (NSCLC). (2006) (4)
Communicating genetic risk: pros, cons, and counsel. (2000) (4)
A staff dialogue on caring for a cancer patient who commits suicide: psychosocial issues faced by patients, their families, and caregivers. (2002) (4)
919 Clinically meaningful improvement in disease-related symptoms by gefitinib (‘Iressa’, ZD1839) in patients with advanced non-small-cell lung cancer: relationship between lung cancer subscale scores and radiographic response and survival (2003) (4)
Polymorphisms in ERCC 1 and Grade 3 or 4 Toxicity in Non – Small Cell Lung Cancer Patients (2005) (4)
In vivo assessment of the effects of bevacizumab in advanced non-small cell lung cancer (NSCLC). (2010) (3)
P-565 A Phase II study of KOS-862 (Epothilone D) as second-linetherapy in non-small cell lung cancer (2005) (3)
9020 POSTER DISCUSSION Use of Bevacizumab (BV) After Induction Therapy is Associated With Survival Benefit in Patients (pts) With Non-small Cell Lung Cancer (NSCLC) in the ARIES Observational Cohort Study (OCS) (2011) (3)
Phase I trial and pharmacokinetic study of ISIS 5132 combined with carboplatin and paclitaxel for advanced non-small cell lung cancer (2000) (3)
Cumulative Exposure to Bevacizumab (BV) After Disease Progression (PD) Correlates with Survival in Non-Small Cell Lung Cancer (NSCLC): A Time-Dependent Analysis of the Aries Observational Cohort Study (2012) (3)
9006 Safety of bevacizumab (BV) combined with chemotherapy (CTX) in patients (pts) with non-small cell lung cancer (NSCLC): interim results from the ARIES Lung observational cohort study (OCS) (2009) (3)
Development of cavitation while on bevacizumab (BV) therapy in patients (pts) with non-small cell lung cancer (NSCLC): Results from ARIES-A bevacizumab (BV) treatment observational cohort study (OCS). (2009) (3)
Randomized phase III trial of gemcitabine/carboplatin with or without iniparib (BSI-201) in patients with previously untreated stage IV squamous non-small cell lung cancer (NSCLC). (2011) (3)
Clinical benefit in NSCLC: the evidence for gefitinib (‘Iressa’, ZD1839) (2003) (2)
Lung cancer symptoms with cetuximab/taxane/carboplatin in first-line advanced NSCLC: Analysis of the BMS099 trial. (2009) (2)
Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 (2008) (2)
Phase I Clinical Trial and Pharmacokinetic Study of the Spicamycin Analog KRN 5500 Administered as a 1-Hour Intravenous Infusion for Five Consecutive Days to Patients with Refractory Solid Tumors (2003) (2)
When a cancer patient commits suicide: psychosocial issues faced by patients, families, and caregivers. (2000) (2)
Phase I dose escalation study of a polymeric micellar formulation of paclitaxel in patients (pts) with refractory non-hematologic cancer (2005) (2)
A staff dialogue on a socially distanced patient: psychosocial issues faced by patients, their families, and caregivers. (2002) (2)
MDM2 polymorphism and recurrence-free and overall survival in early stage non-small cell lung cancer (NSCLC). (2006) (2)
Patient selection for cetuximab in NSCLC: A systematic review of candidate predictive biomarkers. (2010) (2)
Phase I and Pharmacokinetic Study of Ecteinascidin 743 Administered as a 72-Hour Continuous Intravenous Infusion in Patients with Solid Malignancies 1 (2001) (2)
p53 Arg72Pro, MDM2 T309G, CCND1 G870A polymorphisms, histology and esophageal cancer prognosis (2008) (2)
Lung cancer highlights. (2000) (2)
Public Employment Residency Requirements and the Duty to Bargain. (1980) (2)
Radiation dose intensification in limited-stage small-cell lung cancer. (2003) (2)
A method for determining the responsiveness of a tumor to treatments with the epidermal growth factor receptor as a target (2005) (1)
Phase I-II trial of TLK286, a novel glutathione analog prodrug, in combination with carboplatin (C) and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC) (2005) (1)
A phase II study of the safety and efficacy of the MDR inhibitor VX-710 combined with doxorubicin and vincristine in small cell lung cancer. (2006) (1)
Abstract 142: Mutation and immune profiles in early-stage lung squamous cell carcinoma (2016) (1)
Nucleotide excision repair (NER) gene haplotypes and advanced non-small cell lung cancer (NSCLC) prognosis. (2004) (1)
Measures of aggressive care in advanced non-small cell lung cancer (NSCLC) patients (2007) (1)
9090 POSTER Cumulative Exposure to Bevacizumab (BV) After Induction Therapy (tx) Correlates With Increased Survival in Patients (pts) With Non-small Cell Lung Cancer (NSCLC) (2011) (1)
Novel Agents in theTreatment of Lung Cancer : Advances in EGFR-Targeted Agents (2006) (1)
Brief Report of Biweekly Pemetrexed and Gemcitabine in Elderly Patients with Non-small Cell Lung Cancer (2009) (1)
Polymorphisms of DNA repair and glutathione s-transferase genes and progression-free survival (PFS) in treated advanced esophageal cancer (EC) patients (2004) (1)
One-item scale is valid for rapid screening of fatigue in thoracic oncology patients (2005) (1)
Preliminary Treatment Patterns and Safety Outcomes for Non—Small-Cell Lung Cancer from ARIES, a Bevacizumab Treatment Observational Cohort Study (2008) (1)
Lung cancer. (2001) (1)
Point/Counterpoint Counterpoint: The Myeloperoxidase 463 G3 A Polymorphism Does Not Decrease Lung Cancer Susceptibility in Caucasians 1 (2002) (1)
Lung Cancer: Advances and Controversies (2005) (1)
Neo-adjuvant radiation, cisplatin, 5-FU +/- paclitaxel in locally advanced esophageal cancer. (2004) (1)
CHEMOTHERAPY (CT) PLUS CETUXIMAB AS 1ST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): META-ANALYSIS OF INDIVIDUAL PATIENT DATA (2010) (1)
Abstract 89: Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma (2016) (0)
Utility of Schwartz Center Rounds in fostering compassion, communication, teamwork, and caregiver support. (2009) (0)
P-99 MnSOD, p53, XRCC1 polymorphisms and non-small cell lung cancer risk (2003) (0)
A Phase I Clinical Trial of Sequentially Administered Doxorubicin and Topotecan in Refractory Solid Tumors 1 (2002) (0)
Capecitabine in colorectal, breast, and other solid tumors: novel therapeutic approaches. Selected abstracts from ASCO 2003. (2003) (0)
Nucleotide excision repair (NER) gene haplotypes and advanced non-small cell lung cancer (NSCLC) prognosis (2004) (0)
PO-1509 Tumours have a sex-relevance to the multifunctional oncoprotein Y-box binding protein-1 (YB-1) (2021) (0)
FDG uptake at sequential intervals after radiotherapy (RT) or RT of chemo-radiotherapy (CT+RT) and its predictive value for clinical outcome of primary lung cancer (2007) (0)
O-12 The cost effectiveness (CE) and cost to medicare of gefitinib (Iressa; ZD1839) for the third-line treatment of non-small cell lung cancer (NSCLC): Can medicare afford the bill? (2003) (0)
Polymorphisms of DNA repair and glutathione s-transferase genes and progression-free survival (PFS) in treated advanced esophageal cancer (EC) patients. (2004) (0)
O-84 Gender, MPO and MnSOD polymorphisms and non-small cell lung cancer risk (2003) (0)
Molecular targeted therapy of lung cancer (2006) (0)
P1-132: Phase II study of erlotinib plus bevacizumab in patients with previously treated malignant pleural mesothelioma (2007) (0)
Building a better therapy for stage IIIA non-small cell lung cancer. (2002) (0)
Bayesian analysis of the International Adjuvant Lung Trial (IALT): Should it change practice? (2004) (0)
Family caregiver satisfaction with early palliative care for advanced non-small cell lung cancer (NSCLC) (2007) (0)
O-171 Polymorphisms of DNA repair and xenoebiotic metabolism genes affect overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with platinum agents (2003) (0)
Racism in the chemotherapy infusion unit: a nurse's story. (2008) (0)
A pilot study of an exercise program for patients with advanced non-small cell lung cancer (2008) (0)
Stage and histology influence the relationship between MDM2 promoter polymorphism and esophageal cancer and overall survival (OS) (2007) (0)
A Phase II Study of Weekly Paclitaxel in Elderly Patients with Advanced Non-Small Cell Lung Cancer 1 (2001) (0)
Early palliative care (PC) in advanced non-small cell lung cancer (NSCLC) is feasible (2005) (0)
P-337 Polymorphism of the xenobiotic metabolizing genes,MPO and NQO1, and overall survival (OS) in advanced stage non-small cell lung cancer (NSCLC) patients (2003) (0)
Reply to I. Floriani et al (2010) (0)
Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once aWeek for 3 of 4 Weeks in Patients with Advanced SolidTumors (2008) (0)
Recent Advances in the Treatment of Stage IIIA Lung Cancer (2003) (0)
Role of Antimicrobial Stewardship in Infection Prevention (2014) (0)
P-208 A phase II study of J-107088 in previously treated patients with advanced non-small cell lung cancer (NSCLC) (2003) (0)
Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC. (2011) (0)
APhase I Study with Neratinib ( HKI-272 ) , an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor , in Patients with Solid Tumors (2009) (0)
Prosecutorial Misuse of the Peremptory Challenge to Exclude Discrete Groups from the Petit Jury: Commonwealth v. Soares (1980) (0)
Method for determining the response of cancer to treatments directed at the epidermal growth factor receptor (2005) (0)
Apoptosis gene polymorphisms and the risk of non-small cell lung cancer (2008) (0)
DNA repair polymorphisms and overall survival in early stage non-small cell lung cancer (2007) (0)
P-846 Fatigue screening in a thoracic oncology clinic (2005) (0)
The ERCC1 C8092A polymorphism and grade III/IV gastrointestinal (GI) toxicity in non-small cell lung cancer (NSCLC) patients treated with chemoradiation (2004) (0)
MMP1 1G/2G promoter polymorphism and risk of esophageal adenocarcinoma (2007) (0)
Y1-03: How to integrate biomarkers in clinical trials (2007) (0)
Identifying Agents to Test in Phase III Trials (2004) (0)
O-166 Validity of one-item scale for rapid screening of fatigue in thoracic oncology patients (2005) (0)
2041 DEMONSTRATION OF THE VARIABILITY OF THE DIFFERENT TOTAL PSA ASSAYS CURRENTLY IN USE THROUGHOUT IRISH HOSPITALS (2011) (0)
The ERCC1 C8092A polymorphism and grade III/IV gastrointestinal (GI) toxicity in non-small cell lung cancer (NSCLC) patients treated with chemoradiation. (2004) (0)
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. (2017) (0)
Esophagitis Identified in Restaging FDG-PET after Radiotherapy or Chemo-radiotherapy in Lung Cancer (2008) (0)
Polymorphisms in ERCC2 and overall survival (OS) in early stage non-small cell lung cancer (NSCLC) (2005) (0)
Commentary (Sequist/Lynch): EGFR Inhibitors in Lung Cancer (2005) (0)
Palliative Care Study (2010) (0)
9089 POSTER Exploratory Predictive Biomarker Assessment in the BMS099 Study of Cetuximab in NSCLC (2011) (0)
Advances in Non-Small Cell Lung Cancer 2014 (2013) (0)
9073 POSTER Clinical Outcomes for Bevacizumab (BV)-treated Elderly Patients With Non-small Cell Lung Cancer (NSCLC) – Results From the ARIES Observational Cohort Study (OCS) (2011) (0)
The NAD ( P ) H : quinone Oxidoreductase 1 Gene Polymorphism and Lung Cancer : Differential Susceptibility Based on Smoking Behavior 1 (2001) (0)
A Phase II Trial of the Cyclin-dependent Kinase Inhibitor Flavopiridol in Patients with Previously Untreated Stage IV Non-Small Cell Lung Cancer 1 (2001) (0)
I-97. Clinical benefit in NSCLC: The evidence for Gefitinib (“Iressa”) (2003) (0)
The P hase I II T rial i n t he E ra o f T argeted T herapy: Unraveling t he " Go o r N o G o" D ecision (2003) (0)
Screening for cancer-related fatigue (CRF) in a thoracic oncology clinic is feasible (2005) (0)
Molecular staging of NSCLC: 2006 (2006) (0)
Epidermal growth factor receptor (EGFR) mutation testing in non-small cell lung cancer (NSCLC) patients (pts). (2016) (0)
Small Cell Lung Cancer − Gender , and the Risk of Non Vascular Endothelial Growth Factor Genotypes , Haplotypes , (2008) (0)
Mucoepidermoid Tumors of the Lung (2006) (0)

This paper list is powered by the following services:

Other Resources About Thomas Lynch

en.wikipedia.org

What Schools Are Affiliated With Thomas Lynch ?

Thomas Lynch is affiliated with the following schools: